Metastatic Malignant Melanoma Clinical Trial
Official title:
A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.
The purpose of this study is to compare efficacy of bevacizumab monotherapy with standard chemotherapy (DTIC) in patients with metastatic malignant melanoma. In addition, we want to evaluate the predictive value of a set biomarkers associated with vascular endothelial growth factor (VEGF) dependent angiogenesis. Also, we aim to identify mechanisms causing acquired resistance to treatment with bevacizumab and escape mechanisms caused by other angiogenic growth factors than VEGF. Finally, we want to analyze safety and influence on outcome variables by primary prevention of bevacizumab induced hypertension by low dose beta blockers in comparison with an ACE inhibitor.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00533702 -
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT02617849 -
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
|
Phase 2 | |
| Terminated |
NCT00304200 -
Temodar and Sutent as Therapy for Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01654692 -
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
|
Phase 2 | |
| Completed |
NCT02350972 -
Inducing Systemic Immunity and Regressions in Metastatic Melanoma
|
Phase 1 | |
| Completed |
NCT00625768 -
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
|
Phase 1 | |
| Terminated |
NCT00961844 -
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00462423 -
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
|
Phase 2 |